China’s Cellular Biomedicine Group Announces Reverse Merger
Cellular Biomedicine Group (CBMG), a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group. EastBridge is a  US  entity that helps companies (usually from  China  or other Asia-Pacific countries) go public. CBMG is testing progenitor and dendritic cell therapies as treatments for a wide variety of diseases, including cancer and osteoarthritis. Both of CMBG’s facilities are in  China , and its products are aimed at the  China  market. More details.... Stock Symbol: (OTCQB: EBIG) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here